Semaglutide

A significant community practice involves using semaglutide at doses below the standard escalation protocol — 'microdosing' at 0.1-0.25mg weekly rather than the standard 0.25mg starting dose. The rationale: lower doses produce meaningful appetite suppression with substantially fewer GI side effects; for individuals who are primarily seeking metabolic/cardiovascular support rather than maximum weight loss, sub-therapeutic doses may provide a favorable side-effect-to-benefit ratio; cost reduction in compounded formulations. Evidence base for microdosing: the European Congress on Obesity 2024 study found that lower doses of semaglutide were as effective as higher doses in some populations when combined with lifestyle changes. This is limited evidence but directionally consistent with the principle that not everyone needs 2.4mg to achieve clinical goals. The important caveat: 'microdosing' in the community is not a validated protocol and should not be confused with the SELECT cardiovascular outcomes evidence (which used 2.4mg). The full cardiovascular benefit established in SELECT may require the 2.4mg dose — this has not been studied at lower doses.

The GLP-1 receptor (GLP-1R) is a class B G-protein coupled receptor expressed throughout the body — but the distribution pattern is key to understanding the breadth of semaglutide's effects. Pancreatic beta cells: GLP-1R activation stimulates glucose-dependent insulin secretion and inhibits glucagon — the primary anti-diabetic mechanism; crucially, this effect is glucose-dependent (only active when blood glucose is elevated), which is why GLP-1 agonists don't cause hypoglycemia in isolation. Hypothalamus and brainstem (arcuate nucleus, NTS, area postrema): the primary appetite suppression mechanism; GLP-1R activation reduces NPY/AgRP hunger-promoting neurons and increases POMC/CART satiety neurons; the brainstem area postrema (accessible without a blood-brain barrier) provides nausea signaling as a side effect of the same appetite suppression mechanism. Vagal afferents: GLP-1R on vagus nerve fibers relay satiety signals from the GI tract to the brainstem — explaining why gastric emptying is slowed. Cardiovascular system (heart, endothelium, smooth muscle): GLP-1R in the cardiovascular system contributes to anti-inflammatory, anti-atherosclerotic, and cardioprotective effects that appear to extend beyond the metabolic effects of weight loss alone — the SELECT finding that CV benefit was independent of weight loss magnitude confirmed this. Kidney: natriuretic effects contributing to blood pressure reduction. Liver: reduces hepatic glucose output; NAFLD/MASLD improvement.

Semaglutide's weight loss effect operates through multiple CNS mechanisms simultaneously. The hypothalamic effect: GLP-1R activation in the arcuate nucleus directly modulates the energy balance circuitry — suppressing hunger-promoting AgRP/NPY neurons and activating satiety-promoting POMC/CART neurons. This is not simply 'feeling less hungry' — it is a recalibration of the body's defended energy set point. Subjects on semaglutide at 2.4mg report reduced food cravings, reduced motivation to eat, and reduced reward value of highly palatable foods — consistent with GLP-1R's role in the mesolimbic dopamine system. The food reward component: GLP-1R is expressed in the ventral tegmental area and nucleus accumbens — the core of the dopamine reward circuit. This is why semaglutide reduces not only hunger (the homeostatic drive to eat) but also hedonic eating (eating for pleasure rather than need). Exploratory data suggests reduced alcohol and addictive behavior in GLP-1 agonist users — consistent with this reward pathway modulation. The gastric slowing effect: delayed gastric emptying reduces postprandial glucose spikes and prolongs the physical sensation of fullness after eating — adding to the caloric reduction.

The SELECT trial's finding that cardiovascular benefit was independent of weight loss magnitude was one of the most pharmacologically significant observations in recent cardiology. The mechanisms: Anti-inflammatory effects — GLP-1R activation in macrophages and endothelial cells reduces inflammatory cytokine production (TNF-α, IL-6, CRP); this systemic anti-inflammatory effect persisted even in subjects who lost minimal weight. Anti-atherosclerotic effects — reduced endothelial inflammation reduces plaque progression; some experimental evidence for direct plaque stabilisation. Renal effects — blood pressure reduction through natriuresis (reduced kidney sodium reabsorption); consistent modest BP reductions observed across all STEP trials. The cardiac-specific effects — direct GLP-1R activation on myocardium may reduce ischemic injury and improve cardiac function independently of weight effects. The mechanistic conclusion: semaglutide is a cardiometabolic drug, not merely a weight loss drug. Its cardiovascular benefits appear to arise from multiple pathways operating simultaneously, of which weight loss is one important but not exclusive contributor.

Trial

Population

Duration

Weight Loss

Key Finding

STEP 1 (NEJM 2021)

n=1,961; obesity (BMI ≥30) or overweight + ≥1 comorbidity; no T2D

68 weeks

-14.9% sema vs -2.4% placebo (net -12.5%)

50.5% achieved ≥15% WL; 32.0% achieved ≥20%; Grade A

STEP 2 (NEJM 2021)

n=1,210; T2D + obesity

68 weeks

-9.6% sema vs -3.4% placebo

HbA1c -1.6% sema vs -0.4% placebo; Grade A

STEP 3 (NEJM 2021)

n=611; obesity + intensive lifestyle intervention

68 weeks

-16.0% sema + lifestyle vs -5.7% lifestyle alone

Shows significant additive benefit over lifestyle alone; Grade A

STEP 4 (NEJM 2022)

n=803; 20 weeks sema then randomised to continue vs switch placebo

48 more weeks

Continue sema: -7.9% additional; switch placebo: +6.9% regain

The key discontinuation trial — confirms weight rebound with cessation; Grade A

STEP 5 (Lancet DM 2022)

n=304; long-term obesity; 2 years

104 weeks

-15.2% sema vs -2.6% placebo

2-year durability confirmed; weight loss maintained; Grade A

STEP 8 (JAMA 2022)

n=338; head-to-head sema 2.4mg vs liraglutide 3.0mg

68 weeks

-15.8% sema vs -6.4% liraglutide

Sema significantly superior to liraglutide for weight loss; Grade A head-to-head

SELECT (NEJM 2023; 4-year data Nature Medicine 2024): Lincoff [4] AM et al. for SELECT Trial Investigators. The landmark cardiovascular outcomes trial for semaglutide in obesity without diabetes. Design: double-blind, placebo-controlled, event-driven; n=17,604 adults with overweight (BMI ≥27) or obesity and established atherosclerotic CVD; no diabetes at baseline. Randomised to semaglutide 2.4mg weekly vs placebo; mean follow-up 39.8 months. Primary outcome: composite of cardiovascular death, nonfatal MI, nonfatal stroke (MACE). RESULTS: Hazard ratio 0.80 (95% CI 0.72-0.90; p<0.001) — 20% relative risk reduction in MACE. Absolute risk reduction: 1.5 percentage points. NNT to prevent one MACE event: approximately 67. Individual components: cardiovascular death (HR 0.81), nonfatal MI (HR 0.72), nonfatal stroke (HR 0.83). Weight loss sustained at 4 years: -10.2% semaglutide vs -1.5% placebo. Critical finding: the cardiovascular benefit was not explained by weight loss magnitude — even participants who lost minimal weight showed cardiovascular benefit, suggesting mechanisms beyond adiposity reduction. This led to the 2024 FDA approval for cardiovascular risk reduction as a standalone indication.

The SELECT cardiovascular benefit is the most important clinical trial finding in modern obesity pharmacology. It established, for the first time with a large adequately-powered RCT, that treating obesity with a pharmacological agent produces primary cardiovascular outcome benefit beyond what would be expected from weight loss alone. This moved semaglutide from a 'weight loss drug' to a 'cardiometabolic drug' in the clinical pharmacology landscape.

Outcome

Grade

Magnitude

Trial Evidence

Weight loss — obesity

A

Net -12.5% vs placebo at 68 wks (STEP 1); maintained at 2 years (STEP 5)

STEP 1-8; multiple meta-analyses

Weight loss — T2D

A

Net -6.2% vs placebo at 68 wks

STEP 2; SUSTAIN series

Glycemic control (T2D)

A

HbA1c -1.6% vs -0.4% (STEP 2); similar across SUSTAIN trials

STEP 2; SUSTAIN 1-10

Cardiovascular outcomes (MACE)

A

HR 0.80; 20% RRR (SELECT); HR 0.74 in SUSTAIN-6 (T2D)

SELECT; SUSTAIN-6

Blood pressure

A

Systolic BP -2 to -6 mmHg vs placebo

Multiple STEP and SUSTAIN trials

Lipids

A

LDL -3 to -5%; TG -15-20% vs placebo

STEP/SUSTAIN consistent finding

Heart failure (HFpEF)

A

STEP-HFpEF: significant improvement in HF symptoms and exercise capacity

STEP-HFpEF (NEJM 2024)

NAFLD/MASLD

B

Hepatic fat reduction; MASLD improvement

ESSENCE trial; SUSTAIN subanalyses

Kidney function

B

eGFR preservation; FLOW trial ongoing (positive results 2024)

FLOW trial; SUSTAIN subanalyses

Addictive behaviors

C

Exploratory: reduced alcohol, tobacco use signals in SELECT

Observational SELECT subanalyses

The STEP 4 trial (NEJM 2022): Rubino et al. After 20 weeks of semaglutide 2.4mg (achieving ~11% weight loss), participants were randomised to continue semaglutide or switch to placebo. At 48 additional weeks (68 weeks total): the semaglutide continuation group lost a further -7.9%; the placebo-switch group gained +6.9% — rapidly reversing most of their prior loss. The STEP 1 extension study: the most comprehensive withdrawal data. Participants who completed the 68-week STEP 1 trial and then discontinued semaglutide were followed for an additional 52 weeks (to week 120). Findings: within one year of stopping, participants regained a mean of 11.6 percentage points of weight — approximately two-thirds of the total weight lost. By week 120, the semaglutide arm had returned to approximately 2/3 of baseline weight. The meta-analysis evidence (Cureus 2025; Kolli [6] et al.): systematic review and meta-analysis of eight studies evaluating weight regain after GLP-1 agonist discontinuation. Semaglutide showed the highest weight regain: mean difference -5.15 kg (95% CI -5.27 to -5.03). Liraglutide: -1.50 kg. The eClinicalMedicine/Lancet systematic review (November 2025): confirmed the rebound pattern; noted a systolic blood pressure rebound of +7.09 mmHg for semaglutide after discontinuation — greater than liraglutide (+1.56 mmHg). The mechanistic explanation: semaglutide works by pharmacologically suppressing the appetite/energy balance circuits that defend elevated body weight. When the pharmacological suppression is removed, these circuits reassert themselves. The 'defended weight' concept from obesity biology explains why: the body treats its elevated weight set point as normal and works to restore it when the drug effect is removed.

THE CHRONIC DISEASE FRAMING — THE MOST HONEST CLINICAL FRAMEWORK FOR SEMAGLUTIDE

Semaglutide treats obesity the way antihypertensives treat hypertension and statins treat hyperlipidemia: effectively during treatment, with return of the underlying condition upon discontinuation. Stopping lisinopril raises blood pressure. Stopping atorvastatin raises LDL. Stopping semaglutide raises body weight. This is not a failure of the drug — it is the nature of the underlying condition. Obesity is a chronic disease with neurobiological and hormonal drivers that the drug suppresses but does not cure. The clinical and behavioral implication: semaglutide is most appropriately framed as a medication that may need to be taken indefinitely to maintain its effects, the same way most antihypertensives and statins are taken indefinitely. This framing has significant implications: cost (long-term expense); access (medication availability, insurance); side effects (long-term tolerability); and the psychological relationship with the treatment (chronic medication vs weight loss course). Community users approaching semaglutide as a 'weight loss course' with a planned end date should understand this pharmacological reality.

The Epic Research real-world study (January 2024) [7]: n=20,274 patients prescribed semaglutide who lost at least 5 pounds; followed 1 year after discontinuation. This is real-world data from 236 health systems representing 227 million patient records — the largest real-world semaglutide discontinuation dataset. Findings: 17.7% of semaglutide users regained ALL weight they had lost (or exceeded baseline). 55.7% either maintained their weight or continued losing weight at 1 year post-discontinuation. The gap between clinical trial (two-thirds regain in 1 year) and real-world (55.7% maintained or continued losing) is significant and reflects: real-world patients make lifestyle changes during semaglutide treatment that persist after stopping; patients who discontinue in real-world settings are not randomly assigned — those who stop may have achieved sustainable habits during treatment; clinical trial populations may be more diverse in their behavioral changes than the highly selected STEP trial participants. The tapering approach (ECO 2024): a study presented at the European Congress on Obesity showed that gradual semaglutide dose tapering over 9 weeks with concurrent lifestyle coaching allowed 85/240 patients who tapered to zero to maintain weight at 26 weeks post-stop, with a mean additional weight loss of -1.5%. This suggests that how you stop matters as much as whether you stop.

• Do not frame semaglutide as a course treatment — frame it as chronic disease management. Discuss with physician whether long-term treatment is appropriate for your situation.
• If discontinuing, taper gradually rather than stopping abruptly — dose tapering over 8-12 weeks may allow some behavioral and metabolic adaptation.
• During treatment, invest in behavioral infrastructure: protein-first dietary patterns, resistance training for muscle preservation, sleep quality, stress management. These habits have the best chance of partial weight maintenance after stopping.
• If the goal is cardiovascular risk reduction (SELECT indication), discontinuation reactivates the underlying risk factors that semaglutide was treating — the CV benefit requires ongoing treatment.
• Real-world outcomes appear meaningfully better than clinical trial data suggests — the trial-to-real-world gap may reflect lifestyle investment during treatment.

GI adverse events are the most common reason for semaglutide discontinuation and the primary dose-limiting factor. Nausea: 44% of semaglutide patients vs 16% placebo (STEP 1). Vomiting: 24% vs 6%. Diarrhea: 30% vs 16%. Constipation: 24% vs 11%. The critical context: the majority of GI side effects are concentrated in the dose escalation phase (weeks 1-20) and substantially resolve at maintenance dose in most patients. In SELECT (over 4 years), GI events during the maintenance phase were substantially less common than during escalation. Management: slow the escalation; avoid high-fat meals (fat slows gastric emptying further); small frequent meals; hydration; temporary dose reduction. Severe persistent GI symptoms warrant dose pause and physician evaluation.

GLP-1 receptors are expressed on thyroid C-cells. In rodent studies, GLP-1 receptor agonists (including semaglutide) caused dose-dependent C-cell hyperplasia and medullary thyroid carcinomas. The FDA black box warning reflects this rodent signal. The crucial human context: human thyroid tissue has far fewer GLP-1 receptors than rodent thyroid, and the rodent finding has not translated to elevated MTC incidence in the millions of human patients who have now been treated with GLP-1 agonists for over a decade. Large pharmacoepidemiological studies have not found significantly elevated MTC risk in GLP-1 agonist users. HOWEVER: the absence of demonstrated risk in available data is not the same as proven safety, particularly for rare cancers with long latency periods. The precautionary principle applies. Absolute contraindications: personal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia type 2 (MEN2). Monitoring: calcitonin surveillance is reasonable in long-term users, particularly if any thyroid nodules or symptoms develop.

Pancreatitis was a theoretical safety concern for GLP-1 agonists due to GLP-1 receptors on pancreatic acinar cells. In practice: the SELECT trial (n=17,604; 4 years) showed pancreatitis incidence was not significantly different between semaglutide and placebo groups. Large post-marketing pharmacovigilance data has not established a clinically meaningful pancreatitis risk increase. However: any patient with a history of pancreatitis should discuss with their physician before initiating semaglutide; symptoms of acute pancreatitis (severe abdominal pain, nausea/vomiting, elevated lipase) warrant immediate medical evaluation and semaglutide discontinuation pending investigation.

One of the most clinically significant but underemphasized aspects of semaglutide-induced weight loss: a substantial fraction of weight lost is lean mass (muscle), not just fat. Studies of GLP-1 agonist weight loss show approximately 25-40% of total weight loss comes from lean mass, compared to 25% from lean mass in caloric restriction alone — suggesting GLP-1 agents may produce somewhat higher lean mass loss relative to fat loss than diet alone. At a -15% total body weight loss, this could represent 3-6% total lean mass reduction. The practical implications: sarcopenia acceleration in elderly patients; reduced resting metabolic rate (accelerating the defended weight return after stopping); reduced physical capacity. Mitigation: high-protein diet (1.2-1.6g protein/kg/day) during treatment; resistance training throughout the treatment period. The combination of semaglutide with a structured resistance training program substantially reduces lean mass loss. This is not a reason to avoid semaglutide but is a critical reason to pair it with protein intake and exercise.

Rapid weight loss of any cause is a known risk factor for gallstone formation (cholelithiasis). Semaglutide-associated gallbladder events (cholelithiasis, cholecystitis) are reported at higher rates than placebo — consistent with rapid weight loss mechanism rather than a drug-specific effect. In STEP 1: gallbladder-related adverse events in 1.6% of semaglutide vs 0.7% placebo. For patients with known gallbladder disease or previous cholelithiasis: physician evaluation warranted; bile acid supplementation (ursodiol) is sometimes used prophylactically during rapid weight loss treatment.

In 2023, the FDA and ESCO (American Society of Anesthesiologists) issued an advisory regarding GLP-1 agonists and anesthesia. Semaglutide's gastric emptying slowing can result in food residue in the stomach even after a standard fasting period before surgery. If a patient vomits or regurgitates during anesthesia with a full or partially-full stomach, aspiration (breathing stomach contents into the lungs) can cause severe aspiration pneumonia. Current guidance: discuss semaglutide use with the anesthesiologist before any planned procedure; some practitioners recommend stopping semaglutide for 1 week (short-acting) to 4-5 weeks (weekly, longer-acting like semaglutide) before elective procedures; for urgent procedures, assume the stomach may not be empty and take precautions. This is an active area of evolving clinical practice — check current ASA guidance.

Tirzepatide (Mounjaro for T2D, Zepbound for obesity): dual GLP-1/GIP receptor agonist developed by Eli Lilly. SURMOUNT-1 Phase 3 (obesity): -22.5% mean weight loss at 72 weeks — significantly greater than semaglutide's -14.9% in STEP 1. Head-to-head SURMOUNT-5 comparison (2025): tirzepatide produced 20% greater weight loss than semaglutide in the head-to-head trial. The mechanism advantage: GIP receptor co-agonism adds additional appetite suppression and metabolic effects beyond GLP-1 alone. The current state: tirzepatide is the more efficacious weight loss agent; semaglutide has a larger cardiovascular outcomes evidence base (SELECT); both have excellent safety profiles. The SURPASS-CVOT tirzepatide cardiovascular outcomes trial (SURPASS-6) results are expected 2025-2026 and will determine whether tirzepatide matches semaglutide's cardiovascular benefit.

CagriSema (Novo Nordisk) = cagrilintide 2.4mg + semaglutide 2.4mg fixed-dose combination. REDEFINE 1 (NEJM June 2025): -22.7% weight loss at 68 weeks vs -14.9% for semaglutide alone — a 7-8 percentage point improvement from the amylin component. CagriSema represents Novo Nordisk's own competitive response to tirzepatide using semaglutide as the GLP-1 backbone with cagrilintide (amylin receptor agonist) providing the additional mechanism. NDA filed Q1 2026; approval expected late 2026/early 2027. For current semaglutide users: adding cagrilintide if/when CagriSema becomes available represents a pharmacologically rational upgrade. The amylin mechanism is completely complementary to GLP-1.

Compound

Mechanism

Phase 3 WL

CV Outcomes

Approval

Semaglutide (Wegovy)

GLP-1 agonist

-14.9% (STEP 1)

SELECT: HR 0.80; 20% MACE reduction (Grade A)

FDA approved (T2D 2017; obesity 2021; CV 2024)

Tirzepatide (Zepbound)

GLP-1 + GIP dual agonist

-22.5% (SURMOUNT-1)

SURPASS-CVOT ongoing; results 2025-2026

FDA approved (T2D 2022; obesity 2023)

CagriSema (Novo Nordisk)

GLP-1 + amylin dual agonist

-22.7% (REDEFINE 1, NEJM 2025)

No CVOT yet

NDA filed Q1 2026; approval pending

Retatrutide (LY3437943)

GLP-1 + GIP + glucagon triple agonist

~24.2% Phase 2 (48 wks)

Phase 3 TRIUMPH-4; ongoing

Phase 3; no approval

Oral semaglutide (Rybelsus)

GLP-1 agonist (oral)

~15% at high doses

SOUL trial (T2D, CV outcomes) positive 2024

FDA approved T2D; obesity oral pending

Ozempic and Wegovy are the same molecule (semaglutide) from the same manufacturer (Novo Nordisk), administered by the same route (weekly SubQ injection), using the same device type. The differences: Ozempic is approved for T2D at doses of 0.5-2.0mg; Wegovy is approved for obesity and cardiovascular risk reduction at doses up to 2.4mg. The clinical trial evidence for weight loss (STEP trials) was conducted at 2.4mg — the Wegovy dose. Using Ozempic at its labeled T2D doses (0.5-1.0mg) for weight loss produces weight loss, but less than the full 2.4mg dose achieves. The reason Ozempic became the popular name for 'GLP-1 weight loss' is that Ozempic launched years before Wegovy and was widely prescribed off-label for weight loss before Wegovy's approval.

This conflates 'works while you take it' with 'is a cure.' Semaglutide works extremely well while you take it. The weight rebound after stopping reflects the pharmacological reality that obesity is a chronic neurobiological disease that GLP-1 agonism suppresses but does not cure. By the same logic, antihypertensives 'don't work' because blood pressure returns when you stop them. The weight rebound data does not diminish the efficacy of semaglutide during treatment — it informs the clinical decision about treatment duration. For most patients with obesity, long-term treatment is the appropriate framework.

Semaglutide's weight loss mechanism includes appetite suppression, but the breadth of the mechanism is categorically different from phentermine. Phentermine: sympathomimetic; releases norepinephrine; primarily produces appetite suppression via adrenergic pathways; no cardiovascular outcome benefit (actually has cardiovascular concern). Semaglutide: GLP-1R agonist; acts on hypothalamic, brainstem, reward, vagal, and peripheral metabolic pathways simultaneously; produces a 20% MACE reduction; reduces systemic inflammation; improves insulin sensitivity and liver function; reduces blood pressure. The SELECT trial result alone distinguishes semaglutide from any previous appetite suppressant. No previously approved weight loss drug has demonstrated cardiovascular outcome benefit.

Pancreatitis was a theoretical concern based on GLP-1 receptor distribution on pancreatic tissue. The SELECT trial (n=17,604; 4 years) did not show a statistically significant difference in pancreatitis incidence between semaglutide and placebo groups. Large post-marketing databases have not established a clinically meaningful elevated pancreatitis risk. The concern is not entirely dismissed — symptomatic pancreatitis during semaglutide treatment should prompt discontinuation and investigation — but the 'semaglutide causes pancreatitis' framing in early media coverage was not substantiated by the large outcomes trial data.

Compounded semaglutide is the same active molecule. The quality of compounding is the issue — not the molecule. Independent assays showed 68-122% potency variance in commercially available compounded semaglutide. At 68% potency, a patient cannot achieve therapeutic doses without substantially exceeding labeled volumes. At 122% potency, a labeled 2.4mg dose delivers ~2.93mg — above the Phase 3 trial dose. The manufacturing standards (cGMP) that branded products must meet are precisely designed to prevent this type of potency variance. Compounded semaglutide from a high-quality 503B facility with independent quality testing is likely close to branded quality. Research chemical semaglutide from an unregulated vendor is an unknown quality product applied to a potent drug where dosing accuracy matters.

Wilding JPH, Batterham RL, Calanna S, et al. (2021) [1]. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 384(11):989-1002. [STEP 1: n=1,961; 68 weeks; -14.9% vs -2.4% placebo; the foundational obesity efficacy trial.]

Rubino D, Abrahamsson N, Davies M, et al. (2021) [2]. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 325(14):1414-1425. [STEP 4: discontinuation trial; confirms weight rebound with cessation.]

Garvey WT, Batterham RL, Bhatta M, et al. (2022) [3]. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 28(10):2083-2091. [STEP 5: 2-year sustained weight loss data.]

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 389(24):2221-2232. [SELECT primary publication: HR 0.80; 20% MACE reduction; n=17,604.]

Lincoff AM et al. SELECT long-term weight loss analysis. Nature Medicine. 30:2049-2057 (2024). [SELECT 4-year weight and anthropometric data; sustained -10.2% at 208 weeks; CV benefit independent of weight loss magnitude.]

Kolli RT, Aoutla S, Jyothi N, et al. (2025). Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of GLP-1 RAs and Other Anti-obesity Drugs. Cureus. PMC12535773. [8-study meta-analysis; semaglutide highest regain -5.15 kg; systematic quantification of rebound.]

Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine (Lancet). November 2025. [Comprehensive rebound meta-analysis; +7.09 mmHg SBP rebound; pooled weight regain confirmed.]

Epic Research. (2024). Many Patients Maintain Weight Loss a Year After Stopping Semaglutide. [n=20,274 real-world; 55.7% maintained weight or continued losing; 17.7% complete weight regain — substantially better than STEP extension trial data.]

• T2D with BMI ≥27: Ozempic or Wegovy are first-line evidence-based options; physician prescription required; Grade A evidence for glycemic control, weight loss, and cardiovascular benefit. Discuss with physician.
• Obesity (BMI ≥30 or ≥27 + comorbidity) without T2D: Wegovy 2.4mg is the evidence-based standard; physician prescription required; Grade A weight loss (STEP) and cardiovascular (SELECT) evidence. Consider as long-term chronic disease management.
• Obesity + established CVD: SELECT indication now FDA-approved for cardiovascular risk reduction — this may shift insurance coverage; 20% MACE reduction is the strongest cardiovascular signal of any obesity treatment.
• Treatment duration: Conceptualize as chronic disease management, not a course. The weight rebound data shows most weight returns within 1 year of stopping. If stopping is planned, taper gradually and invest in behavioral infrastructure during treatment.
• Muscle preservation during treatment: Protein intake 1.2-1.6g/kg/day; resistance training; these are non-optional for minimizing lean mass loss.
• Compounded vs branded: Branded pharmaceutical (Wegovy/Ozempic) via prescription provides guaranteed dosing accuracy; compounded semaglutide from quality 503B facilities is the practical alternative when branded products are inaccessible; research chemical semaglutide lacks quality assurance for a dose-sensitive drug.
• Combination with CagriSema components: Adding cagrilintide (when available as CagriSema) to existing semaglutide provides the amylin mechanism addition: REDEFINE 1 showed +7-8 percentage points additional weight loss. This is the next-step rational upgrade for semaglutide users seeking enhanced efficacy.

— End of Semaglutide —

THE PEPTIDE BIBLE | Semaglutide | For Research & Educational Purposes Only